EYPT
EyePoint, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.38
+0.85%Year over year
Reported trailing growth
- Revenue
- -94.6%
- EBITDA
- -70.3%
- EBIT
- -67.7%
- EPS
- -39.6%
- Free cash flow
- -39.8%
- Operating cash flow
- -40.3%
Forward estimates
Based on analyst estimates
- Revenue
- -69.5%
- EBITDA
- +30.5%
- EPS
- +35.9%
Three-year CAGR
- Revenue
- -8.8%
- EBITDA
- -77.5%
- EBIT
- -66.9%
- Net income
- -77.2%
- EPS
- -36.6%
- Free cash flow
- -86.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026